OC
MCID: OVR042
MIFTS: 83

Ovarian Cancer (OC)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer

MalaCards integrated aliases for Ovarian Cancer:

Name: Ovarian Cancer 57 12 76 53 25 75 37 29 55 6 43 3 15
Ovarian Carcinoma 53 25 73
Adenocarcinoma, Ovarian, Somatic 57 13
Epithelial Ovarian Cancer 75 73
Ovarian Cancer, Somatic 57 13
Neoplasm of Ovary 29 6
Ovarian Neoplasm 12 73
Primary Malignant Neoplasm of Ovary 73
Malignant Neoplasm of the Ovary 25
Malignant Tumor of the Ovary 25
Malignant Neoplasm of Ovary 73
Ovarian Carcinoma, Somatic 57
Malignant Tumour of Ovary 12
Malignant Ovarian Tumor 12
Primary Ovarian Cancer 12
Cancer of the Ovary 25
Tumor of the Ovary 12
Ovarian Neoplasms 44
Ovary Neoplasm 12
Oc 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
ovarian cancer:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 167000
Disease Ontology 12 DOID:2394
ICD10 33 C56
ICD9CM 35 183.0
MeSH 44 D010051
NCIt 50 C4984 C7431
SNOMED-CT 68 93934004
KEGG 37 H00027
SNOMED-CT via HPO 69 263681008 254838004 60718004

Summaries for Ovarian Cancer

NIH Rare Diseases : 53 Ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. Many people with early ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Most cases of ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be "hereditary." Although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as BRCA1 or BRCA2 hereditary breast and ovarian cancer syndrome, Lynch syndrome and Peutz-Jeghers syndrome) and are inherited in an autosomal dominant manner. The best treatment options for ovarian cancer depend on many factors including the subtype and stage of the condition, but may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Ovarian Cancer, also known as ovarian carcinoma, is related to hereditary breast ovarian cancer syndrome and ovarian cancer 1, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer is OPCML (Opioid Binding Protein/Cell Adhesion Molecule Like), and among its related pathways/superpathways are MicroRNAs in cancer and TGF-Beta Pathway. The drugs Abraxane and Abstral have been mentioned in the context of this disorder. Affiliated tissues include testes, ovary and lung, and related phenotypes are abnormality of metabolism/homeostasis and breast carcinoma

Disease Ontology : 12 A female reproductive organ cancer that is located in the ovary.

Genetics Home Reference : 25 Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

OMIM : 57 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases (Chi et al., 2001). These typical features relate to the biology of the disease, which is a principal determinant of outcome (Auersperg et al., 2001). Epithelial ovarian cancer is the most common form and encompasses 5 major histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Epithelial ovarian cancer arises as a result of genetic alterations sustained by the ovarian surface epithelium (Stany et al., 2008; Soslow, 2008). (167000)

MedlinePlus : 43 The ovaries are part of the female reproductive system. They produce a woman's eggs and female hormones. Each ovary is about the size and shape of an almond. Cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. The sooner ovarian cancer is found and treated, the better your chance for recovery. But ovarian cancer is hard to detect early. Women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. Then it is hard to treat. Symptoms may include A heavy feeling in the pelvis Pain in the lower abdomen Bleeding from the vagina Weight gain or loss Abnormal periods Unexplained back pain that gets worse Gas, nausea, vomiting, or loss of appetite To diagnose ovarian cancer, doctors do one or more tests. They include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. Treatment is usually surgery followed by chemotherapy. NIH: National Cancer Institute

CDC : 3 CDC works with partners to reduce the burden of gynecologic cancer in the United States. Learn what CDC is doing.

Novus Biologicals : 56 Tumor markers can be found in the body when cancer is present. They are most often found in the blood or urine, but can also be found in tumors and other tissues. High level of the tumor marker CA125 in the blood strongly suggests ovarian cancer. CA125 is an antigen present on 80% of non-mucinous ovarian carcinomas.

UniProtKB/Swiss-Prot : 75 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

Wikipedia : 76 Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the... more...

Related Diseases for Ovarian Cancer

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Ovarian Benign Neoplasm

Diseases related to Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 602)
# Related Disease Score Top Affiliating Genes
1 hereditary breast ovarian cancer syndrome 34.7 PTEN PALB2 BRIP1 BRCA2 BRCA1
2 ovarian cancer 1 34.5 PIK3CA KRAS ERBB2 CDH1 BRCA2 BRCA1
3 hereditary site-specific ovarian cancer syndrome 33.8 BRCA1 BRCA2
4 breast cancer 33.5 RRAS2 PTEN PIK3CA PALB2 MIR429 MIR200C
5 pancreatic cancer 33.3 PIK3CA PALB2 MIR214 KRAS ERBB2 CTNNB1
6 ovarian clear cell carcinoma 33.0 KRAS PIK3CA PTEN
7 lynch syndrome 33.0 KRAS CTNNB1 BRCA2 BRCA1 BRAF
8 ovarian disease 32.8 AKT1 BRCA1 BRCA2 PTEN
9 ovary epithelial cancer 32.5 PIK3CA KRAS ERBB2 CDH1 BRCA2 BRCA1
10 ovarian serous carcinoma 32.3 MIR200A MIR200C MIR214
11 colorectal cancer 31.5 PTEN PIK3CA MIR200C KRAS ERBB2 CTNNB1
12 adenocarcinoma 31.5 PTEN PIK3CA KRAS ERBB2 CTNNB1 CDH1
13 endometrial cancer 31.4 PTEN PIK3CA MIR200C KRAS ERBB2 CTNNB1
14 lung cancer 31.3 PTEN PRKN PIK3CA MIR429 MIR214 MIR200C
15 carcinosarcoma 31.3 CTNNB1 PTEN PIK3CA KRAS ERBB2
16 prostate cancer 31.2 PTEN PIK3CA MIR214 MIR200B KRAS ERBB2
17 endometriosis 31.2 MIR200A MIR200B PTEN
18 fallopian tube carcinoma 31.1 BRCA1 BRCA2 ERBB2
19 primary peritoneal carcinoma 31.1 BRCA1 BRCA2 ERBB2
20 cervical cancer 30.9 PTEN PIK3CA MIR214 ERBB2 CTNNB1 CDH1
21 endometrial adenocarcinoma 30.9 PTEN KRAS ERBB2 CTNNB1 AKT1
22 melanoma 30.8 PTEN MIR200C MIR200B MIR200A BRAF
23 testicular germ cell tumor 30.8 BRAF MIR200C PTEN
24 squamous cell carcinoma 30.7 PTEN PIK3CA ERBB2 CTNNB1 CDH1 BRAF
25 glioblastoma 30.7 AKT1 BRAF BRCA2 ERBB2 PIK3CA PTEN
26 papillary carcinoma 30.7 BRAF CDH1 ERBB2
27 fanconi anemia, complementation group a 30.7 BRCA1 BRCA2 BRIP1 PALB2
28 gastrointestinal stromal tumor 30.7 AKT1 BRAF KRAS PTEN
29 bladder urothelial carcinoma 30.6 PIK3CA KRAS ERBB2 CTNNB1 CDH1 BRAF
30 pancreas adenocarcinoma 30.6 PIK3CA PALB2 KRAS ERBB2 CTNNB1 CDH1
31 cholangiocarcinoma 30.6 PTEN PIK3CA MIR200B KRAS ERBB2 CTNNB1
32 medulloblastoma 30.6 AKT1 BRCA2 CTNNB1 ERBB2 PIK3CA PTEN
33 lung cancer susceptibility 3 30.6 PRKN PIK3CA MIR200B KRAS ERBB2 CTNNB1
34 squamous cell carcinoma, head and neck 30.6 PTEN PIK3CA MIR214 MIR200A ERBB2 CTNNB1
35 cystadenocarcinoma 30.5 AKT1 ERBB2 PIK3CA
36 li-fraumeni syndrome 30.5 BRCA1 BRCA2 PTEN
37 bilateral breast cancer 30.5 PALB2 ERBB2 BRCA2 BRCA1
38 transitional cell carcinoma 30.5 BRAF CDH1 ERBB2 PTEN
39 peutz-jeghers syndrome 30.4 BRCA2 CTNNB1 PTEN
40 cowden disease 30.4 PTEN PIK3CA BRCA2 BRCA1 AKT1
41 gallbladder cancer 30.4 PIK3CA KRAS ERBB2 CDH1 AKT1
42 glioma 30.4 BRAF BRCA2 ERBB2 PIK3CA PTEN
43 sporadic breast cancer 30.4 PTEN ERBB2 BRCA2 BRCA1
44 ovarian serous cystadenocarcinoma 30.4 PIK3CA ERBB2 BRAF AKT1
45 serous cystadenocarcinoma 30.3 AKT1 ERBB2 PIK3CA
46 uterine corpus serous adenocarcinoma 30.3 BRCA1 ERBB2 PIK3CA
47 in situ carcinoma 30.3 BRCA1 CDH1 ERBB2
48 breast carcinoma in situ 30.3 BRCA1 BRCA2 ERBB2
49 ovary adenocarcinoma 30.3 ERBB2 KRAS PIK3CA
50 breast-ovarian cancer, familial 1 12.4

Comorbidity relations with Ovarian Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Fallopian Tube Carcinoma Hydronephrosis
Intestinal Obstruction Myofibroma
Neutropenia Paralytic Ileus
Peritoneum Cancer Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ovarian Cancer:



Diseases related to Ovarian Cancer

Symptoms & Phenotypes for Ovarian Cancer

Symptoms via clinical synopsis from OMIM:

57
Oncology:
dysgerminoma
breast cancer
ovarian cancer
ovarian papillary adenocarcinoma
serous ovarian cystadenocarcinoma

Lab:
frequent loss of heterozygosity at 6q24-q27


Clinical features from OMIM:

167000

Human phenotypes related to Ovarian Cancer:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 32 HP:0001939
2 breast carcinoma 32 HP:0003002
3 dysgerminoma 32 HP:0100621
4 ovarian papillary adenocarcinoma 32 HP:0006774

UMLS symptoms related to Ovarian Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer according to GeneCards Suite gene sharing:

26 (show all 45)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.49 CTNNB1 KRAS
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.49 BRAF
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.49 CTNNB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.49 KRAS
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.49 BRAF
6 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.49 PIK3CA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.49 AKT1 PIK3CA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.49 BRAF PIK3CA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.49 KRAS
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.49 AKT1 BRAF CTNNB1 KRAS PIK3CA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.49 PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.49 BRAF
13 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.49 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.49 CTNNB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.49 KRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.49 BRAF
17 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.49 BRAF
18 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.49 BRAF
19 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.49 AKT1 PIK3CA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.49 BRAF CTNNB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.49 CTNNB1 KRAS PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.49 AKT1 KRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.49 KRAS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.49 CTNNB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.49 AKT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.49 CTNNB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.49 CTNNB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.49 AKT1 CTNNB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.49 AKT1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.49 KRAS
31 Decreased viability GR00055-A-2 10.35 BRAF KRAS
32 Decreased viability GR00106-A-0 10.35 KRAS
33 Decreased viability GR00221-A-1 10.35 CDH1 KRAS
34 Decreased viability GR00221-A-2 10.35 BRCA1 KRAS
35 Decreased viability GR00221-A-3 10.35 BRCA1
36 Decreased viability GR00221-A-4 10.35 BRAF
37 Decreased viability GR00301-A 10.35 BRAF BRCA1 CDH1 KRAS
38 Decreased viability GR00381-A-1 10.35 BRAF KRAS
39 Decreased viability GR00402-S-2 10.35 BRAF BRCA1 CDH1 KRAS
40 Decreased cell migration GR00055-A-1 9.8 AKT1 BRAF CTNNB1 KRAS PIK3CA
41 Increased cell migration GR00055-A-3 9.56 BRAF CTNNB1 KRAS PIK3CA
42 Decreased viability with cisplatin GR00101-A-4 9.5 BRCA1 BRCA2 BRIP1
43 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 AKT1 BRCA1 BRCA2 PALB2 PRKN PTEN
44 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 AKT1 BRAF BRCA1 BRCA2 BRIP1 PALB2
45 Synthetic lethal with cisplatin GR00101-A-1 9.13 BRCA1 BRCA2 BRIP1

MGI Mouse Phenotypes related to Ovarian Cancer:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
2 cardiovascular system MP:0005385 10.35 AKT1 BRAF BRCA1 CDH1 CTNNB1 ERBB2
3 behavior/neurological MP:0005386 10.32 AKT1 BRAF BRCA1 BRCA2 CTNNB1 ERBB2
4 growth/size/body region MP:0005378 10.32 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
5 embryo MP:0005380 10.28 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
6 homeostasis/metabolism MP:0005376 10.27 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
7 endocrine/exocrine gland MP:0005379 10.26 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
8 integument MP:0010771 10.26 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
9 neoplasm MP:0002006 10.22 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
10 digestive/alimentary MP:0005381 10.15 BRAF BRCA1 BRCA2 CDH1 CTNNB1 ERBB2
11 nervous system MP:0003631 10.15 AKT1 BRAF BRCA1 BRCA2 BRIP1 CTNNB1
12 muscle MP:0005369 10.09 AKT1 BRAF BRCA1 CTNNB1 ERBB2 KRAS
13 limbs/digits/tail MP:0005371 10.06 BRAF BRCA1 BRCA2 CTNNB1 ERBB2 KRAS
14 normal MP:0002873 10.02 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
15 reproductive system MP:0005389 9.9 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
16 pigmentation MP:0001186 9.65 BRAF BRCA1 CTNNB1 KRAS PTEN
17 respiratory system MP:0005388 9.56 AKT1 BRAF BRCA1 CTNNB1 ERBB2 KRAS
18 skeleton MP:0005390 9.32 AKT1 BRAF BRCA1 BRCA2 CTNNB1 ERBB2

Drugs & Therapeutics for Ovarian Cancer

FDA approved drugs:

(show top 50) (show all 228)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Abstral 18 FENTANYL (citrate) ProStrakan January 2011
3
Actiq 18 FENTANYL (citrate) Anesta Corporation November 1998
4
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
5
Afinitor 18 49 EVEROLIMUS Novartis March 2009
6
Akynzeo 18 49 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
7
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
8
Aloxi 18 49 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
9
Anexsia 18 ACETAMINOPHEN; HYDROCODONE BITARTRATE Mallinckrodt Group August 1996
10
Anzemet 18 DOLASETRON MESYLATE Hoechst Marion Roussel February 1998
11
Aredia 18 49 PAMIDRONATE DISODIUM Chiron August 1996
12
Arimidex 18 49 ANASTROZOLE AstraZeneca January 1996
13
Aromasin Tablets 18 49 EXEMESTANE Pharmacia & Upjohn October 21. 1999
14
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
15
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
16
Avastin 18 49 BEVACIZUMAB Genentech July 2009
17
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
18
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
19
Blincyto 18 49 BLINATUMOMAB Amgen December 2014
20
Bosulif 18 49 BOSUTINIB MONOHYDRATE Pfizer September 2012
21
Bromfenac 18 BROMFENAC SODIUM Duract, Wyeth-Ayerst Laboratories July 1997
22
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
23
Campath 18 49 ALEMTUZUMAB Berlex Laboratories May 2001
24
CEA-Scan 18 Immunomedics April 1996
25
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
26
Clolar 18 49 CLOFARABINE Genzyme December, 2004
27
Cometriq 18 49 CABOZANTINIB S-MALATE Exelixis November 2012
28
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
29
Degarelix 18 49 degarelix Ferring Pharmaceuticals December of 2008
30
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
31
Elitek 18 49 RASBURICASE sanofi-aventis October 2009
32
Ellence 18 49 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
33
Elliotts B Solution 18 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
34
Eloxatin 18 49 OXALIPLATIN Sanofi-aventis August 2002
35
Emend 18 49 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
36
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
37
Erivedge 18 49 VISMODEGIB Genentech January 2012
38
Erwinaze 18 49 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
39
Ethyol 18 AMIFOSTINE Alza December 8, 1995
40
Eulexin 18 FLUTAMIDE Schering-Plough June 1996
41
Evista 18 49 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
42
Farydak 18 49 PANOBINOSTAT LACTATE Novartis February 2015
43
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
44
Femara 18 49 LETROZOLE Novartis January 2001
45
Feridex I.V. 18 FERUMOXIDES Advanced Magnetics February 1996
46
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
47
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
48
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
49
Gazyva 18 49 OBINUTUZUMAB Genentech October of 2013
50
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996

Drugs for Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 669)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peppermint Approved Phase 4
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
4
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
5
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
6
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
7
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
8
Ferrous fumarate Approved Phase 4,Not Applicable,Early Phase 1 141-01-5
9
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 763113-22-0 23725625
10
Tranexamic Acid Approved Phase 4 1197-18-8 5526
11
Aprepitant Approved, Investigational Phase 4,Phase 2,Not Applicable 170729-80-3 6918365 151165
12
Fosaprepitant Approved Phase 4,Phase 2,Not Applicable 172673-20-0 219090
13
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925
14
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 5785 54670067
15
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 11103-57-4, 68-26-8 445354
16
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
17
Substance P Investigational Phase 4,Phase 2,Not Applicable 33507-63-0 44359816
18 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 taxane Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Coagulants Phase 4,Phase 2,Not Applicable
45 Antifibrinolytic Agents Phase 4
46 Hemostatics Phase 4,Phase 2,Not Applicable
47 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Neurokinin-1 Receptor Antagonists Phase 4,Phase 2,Not Applicable
50 neurokinin A Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2513)
# Name Status NCT ID Phase Drugs
1 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
2 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
3 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
4 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
5 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
6 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
7 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
8 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
9 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
10 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
11 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Recruiting NCT03543462 Phase 4
12 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
13 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
14 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Active, not recruiting NCT02476968 Phase 4 Olaparib
15 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
16 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
17 NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. Not yet recruiting NCT03752216 Phase 4 Niraparib
18 Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Not yet recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
19 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
20 Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
21 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
22 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
23 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
24 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
25 Hydralazine Valproate for Ovarian Cancer Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
26 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
27 Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
28 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
29 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
30 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
31 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
32 Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer Unknown status NCT01628380 Phase 3
33 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
34 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
35 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
36 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
37 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
38 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
39 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
40 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy Unknown status NCT02097446 Phase 3
41 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
42 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed NCT01847274 Phase 3 Active comparator: Niraparib;placebo
43 Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
44 Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy Completed NCT00312988 Phase 3 Hycamtin;Gemcitabine
45 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
46 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3 chemotherapy
47 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
48 Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients Completed NCT02421588 Phase 3 Lurbinectedin (PM01183);Pegylated liposomal doxorubicin (PLD);Topotecan
49 Women's Activity and Lifestyle Study in Connecticut Completed NCT02107066 Phase 3
50 An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer Completed NCT00113607 Phase 3 Trabectedin;DOXIL;Dexamethasone

Search NIH Clinical Center for Ovarian Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: ovarian neoplasms

Genetic Tests for Ovarian Cancer

Genetic tests related to Ovarian Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Ovary 29 AKT1 CDH1 CTNNB1 OPCML PIK3CA PRKN
2 Ovarian Cancer 29

Anatomical Context for Ovarian Cancer

MalaCards organs/tissues related to Ovarian Cancer:

41
Testes, Ovary, Lung, Endothelial, T Cells, Prostate, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Ovarian Cancer:

19
The Ovary

Publications for Ovarian Cancer

Articles related to Ovarian Cancer:

(show top 50) (show all 10882)
# Title Authors Year
1
Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry. ( 30387804 )
2019
2
Effects of EIF3B gene downregulation on apoptosis and proliferation of human ovarian cancer SKOV3 and HO-8910 cells. ( 30551537 )
2019
3
ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel. ( 30431082 )
2019
4
Celastrol strongly inhibits proliferation, migration and cancer stem cell properties through suppression of Pin1 in ovarian cancer cells. ( 30389635 )
2019
5
Overview of CD24 as a new molecular marker in ovarian cancer. ( 30317611 )
2019
6
Downregulation of miR-145-5p in cancer cells and their derived exosomes may contribute to the development of ovarian cancer by targeting CT. ( 30365097 )
2019
7
Dihydroartemisinin increases gemcitabine therapeutic efficacy in ovarian cancer by inducing reactive oxygen species. ( 30256439 )
2019
8
CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer. ( 30259564 )
2019
9
KDM6B promotes ovarian cancer cell migration and invasion by induced transforming growth factor-β1 expression. ( 30277596 )
2019
10
Magnolin targeting of ERK1/2 inhibits cell proliferation and colony growth by induction of cellular senescence in ovarian cancer cells. ( 30230030 )
2019
11
CHI3L1 results in poor outcome of ovarian cancer by promoting properties of stem-like cells. ( 30121622 )
2019
12
Low expression of ENC1 predicts a favorable prognosis in patients with ovarian cancer. ( 30125994 )
2019
13
Antrodia salmonea-induced oxidative stress abrogates HER-2 signaling cascade and enhanced apoptosis in ovarian carcinoma cells. ( 30146791 )
2019
14
A prognostic 11 genes expression model for ovarian cancer. ( 28817186 )
2018
15
Theaflavin-3,3'-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells. ( 29301278 )
2018
16
Triptolide antagonized the cisplatin resistance in human ovarian cancer cell line A2780/CP70 via hsa-mir-6751. ( 29966441 )
2018
17
miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8. ( 29436681 )
2018
18
The ubiquitin ligase TRIM56 inhibits ovarian cancer progression by targeting vimentin. ( 28771721 )
2018
19
Precise preoperative diagnosis of struma ovarii with pseudo-Meigs' syndrome mimicking ovarian cancer with the combination of<sup>131</sup>I scintigraphy and<sup>18</sup>F-FDG PET: case report and review of the literature. ( 29391043 )
2018
20
Characteristics of Lynch syndrome associated ovarian cancer. ( 29880284 )
2018
21
Are patients willing to travel for better ovarian cancer care? ( 29079037 )
2018
22
A Miniature Cell Pattern Formation of Ovarian Cancer Cell Lines on Self-Assembling Peptide Nanofiber-Coated Coverslip and<i>In Vitro</i>Chemosensitivity Assay. ( 29442905 )
2018
23
The Yet Unrealized Promise of Ovarian Cancer Screening. ( 29450480 )
2018
24
Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells. ( 29436692 )
2018
25
Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. ( 29450531 )
2018
26
Use of apatinib combined with pemetrexed for advanced ovarian cancer: A case report. ( 29979376 )
2018
27
miR-144 Potentially Suppresses Proliferation and Migration of Ovarian Cancer Cells by Targeting RUNX1. ( 29445078 )
2018
28
Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model. ( 29973223 )
2018
29
MiR-221-3p targets ARF4 and inhibits the proliferation and migration of epithelial ovarian cancer cells. ( 28057486 )
2018
30
Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. ( 29979793 )
2018
31
Molecular insights into the transcriptional regulatory role of thyroid hormones in ovarian cancer. ( 28891089 )
2018
32
Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis. ( 29480828 )
2018
33
Orlistat induces apoptosis and protective autophagy in ovarian cancer cells: involvement of Akt-mTOR-mediated signaling pathway. ( 29974191 )
2018
34
GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer. ( 29973689 )
2018
35
Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer? ( 29967225 )
2018
36
Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study. ( 29451070 )
2018
37
Evaluation of Factors Affecting Lymph Node Metastasis in Clinical Stage I-II Epithelial Ovarian Cancer. ( 29975960 )
2018
38
Palmar fasciitis with polyarthritis-associated ovarian cancer: Case report and literature review. ( 29435290 )
2018
39
Phagocytosis of Extracellular Vesicles Extruded From the Placenta by Ovarian Cancer Cells Inhibits Growth of the Cancer Cells. ( 29040188 )
2018
40
Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells. ( 29251331 )
2018
41
Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety. ( 29134372 )
2018
42
Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients. ( 29782365 )
2018
43
MiR-628-5p decreases the tumorigenicity of epithelial ovarian cancer cells by targeting at FGFR2. ( 29229394 )
2018
44
Paclitaxel and Pazopanib in Ovarian Cancer-Reply. ( 29978183 )
2018
45
Neoantigens in ovarian cancer: embarrassment of riches or needles in a haystack? ( 29980529 )
2018
46
Keratinocyte growth factor binding to fibroblast growth factor receptor 2-IIIb promotes epithelial ovarian cancer cell proliferation and invasion. ( 29970688 )
2018
47
Screening for Ovarian Cancer in Asymptomatic Women. ( 29450509 )
2018
48
Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response. ( 28481779 )
2018
49
Blocking Stemness and Metastatic Properties of Ovarian Cancer Cells by Targeting p70<sup>S6K</sup>with Dendrimer Nanovector-Based siRNA Delivery. ( 29241971 )
2018
50
Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. ( 29303933 )
2018

Variations for Ovarian Cancer

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Cancer:

75
# Symbol AA change Variation ID SNP ID
1 BRCA1 p.Cys61Gly VAR_007757 rs28897672
2 BRCA1 p.Cys1697Arg VAR_020702 rs80356993
3 BRCA1 p.Arg1699Trp VAR_075666 rs55770810
4 CTNNB1 p.Ser37Cys VAR_017625 rs121913403
5 CTNNB1 p.Thr41Ile VAR_017630 rs121913413
6 OPCML p.Pro95Arg VAR_055421 rs137852691
7 PIK3CA p.His1047Arg VAR_026192 rs121913279

ClinVar genetic disease variations for Ovarian Cancer:

6 (show top 50) (show all 571)
# Gene Variation Type Significance SNP ID Assembly Location
1 BRIP1 NM_032043.2(BRIP1): c.139C> G (p.Pro47Ala) single nucleotide variant Uncertain significance rs28903098 GRCh37 Chromosome 17, 59937223: 59937223
2 BRIP1 NM_032043.2(BRIP1): c.139C> G (p.Pro47Ala) single nucleotide variant Uncertain significance rs28903098 GRCh38 Chromosome 17, 61859862: 61859862
3 BRIP1 NM_032043.2(BRIP1): c.2392C> T (p.Arg798Ter) single nucleotide variant Conflicting interpretations of pathogenicity rs137852986 GRCh37 Chromosome 17, 59793412: 59793412
4 BRIP1 NM_032043.2(BRIP1): c.2392C> T (p.Arg798Ter) single nucleotide variant Conflicting interpretations of pathogenicity rs137852986 GRCh38 Chromosome 17, 61716051: 61716051
5 PRKN PARK2, DEL deletion Pathogenic
6 PRKN NM_004562.2(PRKN): c.719C> T (p.Thr240Met) single nucleotide variant Conflicting interpretations of pathogenicity rs137853054 GRCh37 Chromosome 6, 162394349: 162394349
7 PRKN NM_004562.2(PRKN): c.719C> T (p.Thr240Met) single nucleotide variant Conflicting interpretations of pathogenicity rs137853054 GRCh38 Chromosome 6, 161973317: 161973317
8 PTEN NM_000314.6(PTEN): c.388C> T (p.Arg130Ter) single nucleotide variant Pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
9 PTEN NM_000314.6(PTEN): c.388C> T (p.Arg130Ter) single nucleotide variant Pathogenic rs121909224 GRCh38 Chromosome 10, 87933147: 87933147
10 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
11 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
12 OPCML NM_001012393.2(OPCML): c.263C> G (p.Pro88Arg) single nucleotide variant Pathogenic rs137852691 GRCh37 Chromosome 11, 132527098: 132527098
13 OPCML NM_001012393.2(OPCML): c.263C> G (p.Pro88Arg) single nucleotide variant Pathogenic rs137852691 GRCh38 Chromosome 11, 132657203: 132657203
14 RRAS2 NM_001177314.1(RRAS2): c.110A> T (p.Gln37Leu) single nucleotide variant Pathogenic rs113954997 GRCh37 Chromosome 11, 14316390: 14316390
15 RRAS2 NM_001177314.1(RRAS2): c.110A> T (p.Gln37Leu) single nucleotide variant Pathogenic rs113954997 GRCh38 Chromosome 11, 14294844: 14294844
16 CDH1 NM_004360.4(CDH1): c.2512A> G (p.Ser838Gly) single nucleotide variant Conflicting interpretations of pathogenicity rs121964872 GRCh37 Chromosome 16, 68867265: 68867265
17 CDH1 NM_004360.4(CDH1): c.2512A> G (p.Ser838Gly) single nucleotide variant Conflicting interpretations of pathogenicity rs121964872 GRCh38 Chromosome 16, 68833362: 68833362
18 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
19 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
20 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
21 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
22 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
23 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
24 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
25 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
26 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
27 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
28 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
29 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
30 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
31 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
32 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh37 Chromosome 17, 41209082: 41209082
33 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
34 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
35 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
36 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
37 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
38 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
39 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
40 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
41 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
42 ERBB2 NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933370 GRCh37 Chromosome 17, 37881378: 37881378
43 ERBB2 NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933370 GRCh38 Chromosome 17, 39725125: 39725125
44 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
45 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
46 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605
47 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
48 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh38 Chromosome 7, 140753345: 140753345
49 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
50 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214

Cosmic variations for Ovarian Cancer:

9 (show all 44)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 19
2 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 19
3 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 19
4 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 19
5 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 19
6 COSM6904336 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 19
7 COSM14135 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 18:51065518-51065518 19
8 COSM6904335 SMAD2 ovary,NS,carcinoma,adenocarcinoma c.785-1G>C p.? 18:47848688-47848688 19
9 COSM6904334 RET ovary,NS,carcinoma,adenocarcinoma c.3253A>G p.T1085A 10:43128177-43128177 19
10 COSM6904339 PTCH1 ovary,NS,carcinoma,adenocarcinoma c.3074G>A p.R1025H 9:95458107-95458107 19
11 COSM760 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1624G>A p.E542K 3:179218294-179218294 19
12 COSM770 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 19
13 COSM21446 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.3012G>T p.M1004I 3:179234169-179234169 19
14 COSM746 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.263G>A p.R88Q 3:179199088-179199088 19
15 COSM94978 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1034A>T p.N345I 3:179203764-179203764 19
16 COSM766 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 3:179218306-179218306 19
17 COSM564 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 1:114716126-114716126 19
18 COSM580 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 1:114713909-114713909 19
19 COSM522 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>C p.G12A 12:25245350-25245350 19
20 COSM521 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 12:25245350-25245350 19
21 COSM520 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>T p.G12V 12:25245350-25245350 19
22 COSM14065 ERBB2 ovary,NS,carcinoma,adenocarcinoma c.2524G>A p.V842I 17:39725079-39725079 19
23 COSM22992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 7:55174020-55174020 19
24 COSM53264 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 7:55174033-55174033 19
25 COSM6224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 7:55191822-55191822 19
26 COSM53230 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 7:55191846-55191846 19
27 COSM28511 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 7:55173967-55173967 19
28 COSM53225 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704L 7:55173971-55173971 19
29 COSM53232 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 7:55173981-55173981 19
30 COSM53226 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 7:55173958-55173958 19
31 COSM53266 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 7:55174024-55174024 19
32 COSM53224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 7:55174032-55174032 19
33 COSM53213 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 7:55191853-55191853 19
34 COSM53229 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744I 7:55174769-55174769 19
35 COSM53231 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853I 7:55191808-55191808 19
36 COSM12373 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 7:55174018-55174018 19
37 COSM53265 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 7:55191805-55191805 19
38 COSM53235 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827Y 7:55191730-55191730 19
39 COSM28286 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 7:55191743-55191743 19
40 COSM53228 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 7:55173982-55173982 19
41 COSM53227 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 7:55191755-55191755 19
42 COSM22499 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 11:108252824-108252824 19
43 COSM6904304 AR ovary,NS,carcinoma,adenocarcinoma c.2179C>T p.R727C 23:67717483-67717483 19
44 COSM159008 AKT1 ovary,NS,carcinoma,adenocarcinoma c.235C>A p.Q79K 14:104776711-104776711 19

Copy number variations for Ovarian Cancer from CNVD:

7 (show top 50) (show all 8010)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13413 1 1 23549970 Deletion AADACL3 Ovarian cancer
2 13414 1 1 23549970 Deletion AADACL4 Ovarian cancer
3 13415 1 1 23549970 Deletion ACAP3 Ovarian cancer
4 13416 1 1 23549970 Deletion ACOT7 Ovarian cancer
5 13417 1 1 23549970 Deletion ACTL8 Ovarian cancer
6 13418 1 1 23549970 Deletion ACTRT2 Ovarian cancer
7 13419 1 1 23549970 Deletion AGMAT Ovarian cancer
8 13420 1 1 23549970 Deletion AGRN Ovarian cancer
9 13421 1 1 23549970 Deletion AGTRAP Ovarian cancer
10 13422 1 1 23549970 Deletion AJAP1 Ovarian cancer
11 13423 1 1 23549970 Deletion AKR7A2 Ovarian cancer
12 13424 1 1 23549970 Deletion AKR7A3 Ovarian cancer
13 13425 1 1 23549970 Deletion AKR7L Ovarian cancer
14 13426 1 1 23549970 Deletion ALDH4A1 Ovarian cancer
15 13427 1 1 23549970 Deletion ALPL Ovarian cancer
16 13428 1 1 23549970 Deletion ANGPTL7 Ovarian cancer
17 13429 1 1 23549970 Deletion APITD1 Ovarian cancer
18 13430 1 1 23549970 Deletion ARHGEF10L Ovarian cancer
19 13431 1 1 23549970 Deletion ARHGEF16 Ovarian cancer
20 13432 1 1 23549970 Deletion ARHGEF19 Ovarian cancer
21 13433 1 1 23549970 Deletion ATAD3A Ovarian cancer
22 13434 1 1 23549970 Deletion ATAD3B Ovarian cancer
23 13435 1 1 23549970 Deletion ATAD3C Ovarian cancer
24 13436 1 1 23549970 Deletion ATP13A2 Ovarian cancer
25 13437 1 1 23549970 Deletion AURKAIP1 Ovarian cancer
26 13438 1 1 23549970 Deletion B3GALT6 Ovarian cancer
27 13439 1 1 23549970 Deletion C1QA Ovarian cancer
28 13440 1 1 23549970 Deletion C1QB Ovarian cancer
29 13441 1 1 23549970 Deletion C1QC Ovarian cancer
30 13442 1 1 23549970 Deletion C1orf126 Ovarian cancer
31 13443 1 1 23549970 Deletion C1orf127 Ovarian cancer
32 13444 1 1 23549970 Deletion C1orf144 Ovarian cancer
33 13445 1 1 23549970 Deletion C1orf151 Ovarian cancer
34 13446 1 1 23549970 Deletion C1orf158 Ovarian cancer
35 13447 1 1 23549970 Deletion C1orf159 Ovarian cancer
36 13448 1 1 23549970 Deletion C1orf170 Ovarian cancer
37 13449 1 1 23549970 Deletion C1orf174 Ovarian cancer
38 13450 1 1 23549970 Deletion C1orf187 Ovarian cancer
39 13451 1 1 23549970 Deletion C1orf200 Ovarian cancer
40 13452 1 1 23549970 Deletion C1orf64 Ovarian cancer
41 13453 1 1 23549970 Deletion